Contradictions Unveiled: Insights from the Latest Deramiocel Earnings Call on Launch Timelines, AdCom Expectations, and Manufacturing Readiness
Earnings DecryptTuesday, May 20, 2025 12:28 pm ET
2min read
None
BLA Progress and FDA Interactions:
- Capricor Therapeutics has filed a Biologics License Application (BLA) seeking full approval for deramiocel in treating Duchenne muscular dystrophy cardiomyopathy.
- The company is preparing for an FDA advisory committee meeting, considered positive as it provides an opportunity to highlight the strength of their data and supports the potential approval of deramiocel.
Financial Performance:
- Capricor reported $0 in revenues for Q1 2025 due to the full recognition of the U.S. distribution agreement with Nippon Shinyaku, which totaled $40 million in 2024.
- Research and development expenses for Q1 2025 were $16.2 million, excluding stock compensation, compared to $10.1 million in Q1 2024.
Manufacturing Expansion:
- Capricor's San Diego GMP manufacturing facility is fully operational and currently producing doses of deramiocel.
- Expansion plans are underway to build additional clean rooms, with the expansion expected to be operational by mid-to-late 2026 to bolster supply.
Executive Appointments and Partnerships:
- Capricor Therapeutics appointed Michael Binks as Chief Medical Officer, with over 25 years of experience in leading global clinical development.
- The company is working with Nippon Shinyaku for potential European distribution and has extended negotiations through the end of Q2 2025.
BLA Progress and FDA Interactions:
- Capricor Therapeutics has filed a Biologics License Application (BLA) seeking full approval for deramiocel in treating Duchenne muscular dystrophy cardiomyopathy.
- The company is preparing for an FDA advisory committee meeting, considered positive as it provides an opportunity to highlight the strength of their data and supports the potential approval of deramiocel.
Financial Performance:
- Capricor reported $0 in revenues for Q1 2025 due to the full recognition of the U.S. distribution agreement with Nippon Shinyaku, which totaled $40 million in 2024.
- Research and development expenses for Q1 2025 were $16.2 million, excluding stock compensation, compared to $10.1 million in Q1 2024.
Manufacturing Expansion:
- Capricor's San Diego GMP manufacturing facility is fully operational and currently producing doses of deramiocel.
- Expansion plans are underway to build additional clean rooms, with the expansion expected to be operational by mid-to-late 2026 to bolster supply.
Executive Appointments and Partnerships:
- Capricor Therapeutics appointed Michael Binks as Chief Medical Officer, with over 25 years of experience in leading global clinical development.
- The company is working with Nippon Shinyaku for potential European distribution and has extended negotiations through the end of Q2 2025.
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
Comments
No comments yet